

Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome

Talia Eldar-Geva^{1,2,4}, Avraham Ben-Chetrit¹, Irving M. Spitz², Ron Rabinowitz³, Einat Markowitz¹, Tzvia Mimoni¹, Michael Gal¹, Edit Zylber-Haran¹ and Ehud J. Margalioth¹

¹IVF Unit, ²Institute of Hormone Research and ³Ultrasound Unit, Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Ben Gurion University of the Negev, Jerusalem 91031, Israel

⁴To whom correspondence should be addressed. E-mail: gevat@szmc.org.il

BACKGROUND: We evaluated basal and dynamic hormonal markers [(FSH, inhibin B, estradiol and anti-Mullerian hormone (AMH)] during the follicular phase and luteal phase of the menstrual cycle and ultrasonic ovarian morphology as predictors of IVF outcome. **METHODS:** Fifty-six women, aged <38 years, with normal day 3 FSH levels were included prospectively. Serum estradiol, inhibin B and AMH were measured before and 24 h after administration of 300 IU of recombinant FSH on cycle day 3–4 and during the luteal phase. Ovarian volume and antral follicle count (AFC) were evaluated on cycle day 3–4. The predictive value of oocyte number and pregnancy were assessed using uni- and multivariate analysis. **RESULTS:** Poor responders (<6 oocytes) had significantly lower luteal AMH levels, while high responders (>20 oocytes) had significantly higher AFC, AMH and luteal stimulated inhibin B and estradiol than normal responders. Multivariate regression analyses showed that the best models for predicting oocyte number included AFC, follicular phase AMH and stimulated inhibin B. Only AMH showed a significant difference between pregnant and non-pregnant women at both cycle phases. **CONCLUSIONS:** In young women (<38 years), AFC or basal AMH and stimulated inhibin B predict ovarian response for IVF. The only predictor for pregnancy is follicular or luteal phase AMH.

Key words: anti-Mullerian hormone/antral follicle count/dynamic assay/inhibin B/IVF outcome

Introduction

Determination of 'ovarian reserve' is important before any expensive IVF treatment is undertaken. Identification of both low and high responders prior to treatment may decrease cycle cancellation rate and side effects, such as ovarian hyperstimulation syndrome (OHSS). Determination of the probability of pregnancy beforehand is important because of its prognostic value. This allows physicians to evaluate and counsel patients before IVF stimulation and to optimize stimulation protocols or consider other treatment options such as gamete donation or adoption. However, there is no consensus regarding the methods for screening for ovarian reserve or for the probability of pregnancy.

The most common cause for diminution of pregnancy rate is ageing, because of the gradual depletion of the quantity and quality of the follicular pool (Faddy and Gosden, 1996). However, it remains a challenge to identify those young women with normal ovulatory cycles but low ovarian reserve that have a low chance for pregnancy following IVF treatment. Early follicular phase basal FSH (Mausher and Oehninger, 1988; Creus *et al.*, 2000; Chuang *et al.*, 2003), inhibin B (Hall *et al.*, 1999), morphometric ultrasonographic parameters such as antral follicle

count (AFC) (Tomas *et al.*, 1997; Pellicer *et al.*, 1998; Chang *et al.*, 1998; Dumesic *et al.*, 2001) and ovarian volume (Lass *et al.*, 1997; Syrop *et al.*, 1999; Frattarelli *et al.*, 2000) were all shown to be correlated with ovarian response in IVF patients. However, in a meta-analysis, it was concluded that basal FSH is not a useful predictor of IVF outcome (Bancsi *et al.*, 2003), possibly because of intercycle variability (Scott *et al.*, 1990; Bancsi *et al.*, 2004). Several studies found no or limited clinical value in measuring basal early follicular inhibin B as an indicator of pregnancy in IVF patients (Hall *et al.*, 1999; Tinkanen *et al.*, 1999; Creus *et al.*, 2000; Ravhon *et al.*, 2000; Dumesic *et al.*, 2001). AFC may be more useful than basal hormonal markers in predicting ovarian response (Dumesic *et al.*, 2001; Bancsi *et al.*, 2003; Popovic-Todorovic *et al.*, 2003; Yong *et al.*, 2003).

Dynamic tests of ovarian reserve have also been performed. These include the well known clomiphene citrate challenge test (CCCT) (Navot *et al.*, 1987) and the GnRH agonist stimulation test, which involves evaluation of changes in estradiol (Garcia *et al.*, 1990; Winslow *et al.*, 1991; Galtier-Dereure *et al.*, 1996; Ranieri *et al.*, 1998) and inhibin B levels (Ravhon *et al.*, 2000) from cycle day 2 or 3 after its administration. The exogenous

FSH ovarian reserve test (EFORT) analysed change in estradiol (Fanchin *et al.*, 1994) and inhibin B (Dzik *et al.*, 2000; Elting *et al.*, 2001) seen 24 h after the administration of 300 IU of FSH on cycle day 3–5. These dynamic tests were shown to be more sensitive than basal FSH, inhibin B or age (Kwee *et al.*, 2003; Yong *et al.*, 2003). In addition, serum inhibin B levels early during FSH stimulation for IVF correlated highly with the number of oocytes retrieved (Eldar-Geva *et al.*, 2002; Yong *et al.*, 2003).

A new suggestive marker is the dimeric glycoprotein anti-Müllerian hormone (AMH), also termed Müllerian-inhibiting substance, a member of the transforming growth factor- β (TGF- β) superfamily. AMH is produced by granulosa cells from pre-antral and small antral follicles (Durlinger *et al.*, 2002). Serum AMH levels decrease over time (de Vet *et al.*, 2002) and are strongly related to the number of oocytes retrieved for IVF treatment (Seifer *et al.*, 2002; Van Rooij *et al.*, 2002; Fanchin *et al.*, 2003). However, most previous studies that aimed to find the best predictor(s) from the known ones for IVF outcome did not include AMH in their analysis (Kwee *et al.*, 2003; Popovic-Todorovic *et al.*, 2003; Yong *et al.*, 2003).

The aim of our study was to evaluate ultrasonic ovarian morphology (AFC and ovarian volume) and basal and dynamic hormonal markers (FSH, inhibin B, estradiol and AMH) during the follicular and the luteal phases as predictors of oocyte number and pregnancy in young women undergoing IVF treatment.

Materials and methods

Patients

Fifty-six women undergoing IVF treatment were included prospectively in the study. The inclusion criteria were age <38 years, day 3 FSH serum concentrations <10 IU/l, normal ovulatory cycles with a mean cycle length of between 26 and 35 days, and good physical and mental health. Women with endocrine abnormalities, such as hyperprolactinaemia, polycystic ovarian syndrome or thyroid dysfunction, or ovarian cysts >2 cm in diameter were excluded. The causes of infertility were tubal factor in seven and a male factor in 36 patients. In 11 patients, the infertility was unexplained and in two patients it was related to multiple causes. The Shaare-Zedek Medical Center Research Ethics Committee approved the study protocol. Informed consent was obtained from all participants.

Protocol

During the cycle prior to IVF treatment, the following tests were performed: (i) transvaginal ultrasonographic evaluation of the number of 2–10 mm follicles in both ovaries (AFC) and ovarian volume on cycle day 3–4; and (ii) 'FSH challenge test' (FCT) on two occasions, initially on cycle day 3–4 and subsequently during the luteal phase (5–10 days post-ovulation). This involved serum sampling before and 24 h after s.c. administration of 300 IU of recombinant human FSH (Gonal F, Serono, Herzliya, Israel) for determination of FSH, estradiol, inhibin B and AMH. Serum samples were centrifuged at 2000 g within 2 h and stored at -20°C until assayed.

After completion of the luteal FCT, the women were treated with the long downregulation protocol consisting of 0.1 mg/day decapeptyl s.c. (Ferring Ltd, Herzliya, Israel) and after pituitary suppression a daily dose of 150 IU of recombinant FSH (Gonal F; Serono, Israel)

and 150 IU of HMG (Menogon; Ferring Ltd). The dose of gonadotrophins was adjusted from day 5 of stimulation according to the ovarian response. HCG 10 000 IU (Chorigon; Teva, Petach-Tiqua, Israel) was given when at least three follicles >17 mm developed. Oocytes were retrieved transvaginally 36 h later. A maximum of three embryos were transferred. The luteal phase was supported by 600 mg/day vaginal micronized progesterone (Utrogestan; CTS, Petach-Tiqua, Israel) or by 50 mg/day progesterone i.m. (Gestone; Ferring Ltd).

Hormone assays

Serum concentrations of estradiol and FSH were measured using Immulite 2000 (Diagnostic Product Corporation, Los Angeles, CA). Assay sensitivities were 150 pmol/l and 0.1 IU/l, respectively. Inter- and intra-assay coefficients of variation were 9.2 and 4.9% for estradiol and 4.3 and 3.6% for FSH, respectively. Serum inhibin B concentrations were measured using a highly sensitive two-site enzyme-linked immunosorbent assay (ELISA; Serotec, Oxford, UK). The assay sensitivity was 15 pg/ml. Inter- and intra-assay coefficients of variation were 15 and 7%, respectively. AMH concentrations were measured using an ultrasensitive two-site ELISA (Immunotech-Coulter, France). The assay sensitivity was 0.7 pmol/l. Inter- and intra-assay coefficients of variation were 8.7 and 5.3%, respectively.

Statistical analysis

The main outcome measures of our study were the number of oocytes retrieved and ongoing pregnancy. Student's *t*-test, Mann–Whitney U-test and Fisher's exact test were performed for testing for differences between groups, as indicated. Analysis of variance (ANOVA) or Friedman tests were used for repeated measurements. Univariate linear regression analyses were performed, with the number of oocytes retrieved as the dependent variable. Independent variables included diagnosis, treatment cycle number, age, weight, body mass index (BMI), day 3 FSH, AFC, ovarian volume, early follicular phase and mid-luteal phase basal and stimulated estradiol, inhibin B and AMH and their increments (Δ serum hormone level, i.e. stimulated minus basal levels). Multivariate stepwise linear regression analyses of covariance (ANCOVA) were also used. Related variables were not used in the same model. The ability of parameters to discriminate between pregnant and non-pregnant patients was assessed by calculating the area under the receiver operating characteristic curve (ROC_{AUC}). Samples with hormone values below the assay detection limit were assigned values equal to the detection limit of that assay. Results are presented as mean \pm SD, unless otherwise indicated. The SPSS statistical package was used for all statistical analyses. Statistical significance was defined as $P < 0.05$.

Results

Of the 56 women tested, seven had <6 oocytes (poor responders), 32 had 6–19 oocytes (normal responders) and 17 had ≥ 20 oocytes (high responders). The characteristics of the women are presented in Table I. Poor responders had significantly lower luteal phase serum AMH levels, while high responders had significantly higher follicular and luteal phase AMH levels compared with normal responders. High responders had in addition significantly higher AFC, ovarian volume and luteal phase Δ inhibin B and stimulated estradiol.

The net increase in serum FSH 24 h following its administration was similar between the follicular and the luteal phases (3.3 ± 2.2 and 4.1 ± 1.8 IU/l, respectively, $P = 0.11$) and was not associated with any parameter tested. Serum inhibin B

increased in all women 24 h following FSH stimulation, both in the follicular phase and in the luteal phase; the net increase (Δ inhibin B) was higher in the follicular phase (Table I). For each patient, the degree of inhibin B response to FSH was similar in both cycle phases (Friedman test). In contrast to inhibin B and estradiol, AMH did not change 24 h following FSH stimulation, either at the early follicular or at the luteal phase (paired Student's *t*-test).

The number of oocytes retrieved showed highly significant positive correlations with AFC, AMH and follicular phase Δ inhibin B (Table II, Figure 1). Less, but still significant positive correlations were also found with follicular and luteal phase stimulated inhibin B. Negative correlations were found with age and basal FSH.

Significant correlations were found between AFC and some endocrine markers (Table III, Figure 2). The most significant correlations were found with follicular phase inhibin B and AMH. Less significant correlations were found with luteal phase AMH and inhibin B. The correlation between AFC and the number of follicles >10 mm on the day of HCG administration was 0.673 ($P < 0.0001$).

Multiple regression ANCOVA showed that the best model for predicting the number of oocytes included AFC alone (adjusted $r^2 = 0.657$, $P < 0.0001$). Adding endocrine markers to the model did not improve its significance. When only endocrine parameters were entered into the model, the combination of follicular phase AMH ($P < 0.05$) and Δ inhibin B ($P < 0.01$) was selected (adjusted $r^2 = 0.624$, $P < 0.001$).

Twenty-six women conceived as a result of the IVF cycle treatment (46%). The clinical and test results of pregnant and non-pregnant women are presented in Table IV. The only parameter that showed significant difference between the two groups was AMH, at both cycle phases. A cut-off basal AMH (either follicular or luteal) of 18 pmol/l had a positive predic-

tive value of 67% and a negative predictive value of 61% for achieving an ongoing pregnancy ($P < 0.01$). The ROC_{AUC} was 0.75 (95% confidence interval 0.61–0.87, $P = 0.003$).

Discussion

In the current study, we investigated the value of morphometric, basal and dynamic endocrine parameters during the follicular and the luteal phases as predictors of IVF outcome in young women (<38 years old) with normal day 3 FSH (<10 IU/l). While most previous studies and meta-analyses have focused on prediction of low responders (Hendriks *et al.*, 2005), we showed in this study that we could predict, with reasonable accuracy, the number of oocytes to be retrieved as a continuous measurement, thus, both low and high responders could be identified. Using multivariate analysis, we found that the best model for predicting the number of oocytes to be retrieved comprises ultrasonic assessment of AFC. The adding of any endocrine measurements could not improve the significance of the model. However, when only endocrine markers were tested, the combination of follicular phase basal AMH and inhibin B increment following FSH stimulation (Δ inhibin B) was also highly significant. Nevertheless, AMH, either early follicular or luteal, was the only parameter that was significantly different between pregnant and non-pregnant women and could offer significant prognostic value for an ongoing pregnancy.

Our finding that either ultrasonography or endocrine test could predict the ovarian response has major clinical importance. The availability and cost of either ultrasonography or serum hormone assays is different in various countries. The correlation between AFC and inhibin B and AMH, especially in the early follicular phase (Table III), in both this and previous studies (Bancsi *et al.*, 2002; Yong *et al.*, 2003), is

Table I. Characteristics of patients and tests

Variable	Poor responders ($n=7$)	Normal responders ($n=32$)	High responders ($n=17$)
Age (years)	32.1 \pm 6.0	30.4 \pm 4.5	28.7 \pm 4.1
BMI (kg/m ²)	23.5 \pm 4.3	23.7 \pm 5.3	24.3 \pm 6.3
No. of treatment cycles	1.4 \pm 0.8	2.2 \pm 2.2	1.8 \pm 1.6
Follicular phase variables			
Basal FSH (IU/l)	8.3 \pm 1.6	8.3 \pm 3.4	5.8 \pm 2.3
Basal inhibin B (pg/ml)	79.4 \pm 19.8	137.9 \pm 210.6	127.8 \pm 126.5
Stimulated inhibin B (pg/ml)	136.2 \pm 40.4	222.9 \pm 268.7	296.9 \pm 269.1
Δ inhibin B (pg/ml)	56.8 \pm 30.1	85.0 \pm 66.7	169.1 \pm 171.3
Basal AMH (pmol/l)	13.6 \pm 11.3	14.1 \pm 7.5	37.8 \pm 19.3 ^c
Stimulated AMH (pmol/l)	11.0 \pm 6.7	14.1 \pm 7.0	40.3 \pm 22.6 ^b
Basal estradiol (pmol/l)	208 \pm 119	161 \pm 39	161 \pm 59
Stimulated estradiol (pmol/l)	343 \pm 112	283 \pm 155	343 \pm 274
AFC	11.5 \pm 9.2	18.8 \pm 8.5	38.9 \pm 16.7 ^b
Ovarian volume (ml)	8.0 \pm 3.5	13.4 \pm 5.1	36.5 \pm 33.9 ^a
Luteal phase variables			
Basal inhibin B (pg/ml)	29.3 \pm 16.6	29.5 \pm 25.3	64.9 \pm 85.1
Stimulated inhibin B (pg/ml)	49.6 \pm 20.6	72.5 \pm 54.6	218.5 \pm 184.9
Δ inhibin B (pg/ml)	20.3 \pm 20.5	41.3 \pm 49.6	153.6 \pm 109.8 ^a
Basal AMH (pmol/l)	3.6 \pm 1.9 ^d	17.5 \pm 9.3	33.1 \pm 15.8 ^b
Stimulated AMH (pmol/l)	5.5 \pm 5.1 ^b	23.6 \pm 33.0	34.7 \pm 15.9 ^a
Basal estradiol (pmol/l)	451 \pm 151	339 \pm 147	435 \pm 175
Stimulated estradiol (pmol/l)	451 \pm 151	437 \pm 252	737 \pm 367 ^a

^a $P < 0.05$, ^b $P < 0.01$, ^c $P < 0.005$, ^d $P < 0.001$ versus normal responders.

Table II. Significant Pearson’s correlation between oocyte number and test parameters

Variable	<i>r</i> value
Age (years)	−0.275 ^a
Follicular phase variables	
Basal FSH (IU/l)	−0.356 ^a
Stimulated inhibin B (pg/ml)	0.458 ^a
Δ inhibin B (pg/ml)	0.558 ^b
Basal AMH (pmol/l)	0.647 ^b
Stimulated AMH (pmol/l)	0.700 ^b
AFC	0.728 ^b
Luteal phase variables	
Stimulated inhibin B (pg/ml)	0.358 ^a
Δ inhibin B (pg/ml)	0.384 ^a
Basal AMH (pmol/l)	0.518 ^b
Stimulated AMH (pmol/l)	0.576 ^b

^a*P* < 0.05, ^b*P* < 0.001.




Figure 1. Correlation between oocyte number and AFC and AMH in early follicular phase.

explained by the fact that both signify the number of small antral follicles (Durlinger *et al.*, 2002; Pangas *et al.*, 2002).

We found that dynamic endocrine tests were better than basal evaluation of FSH, inhibin B or estradiol in predicting ovarian response. This is similar to findings in previous studies (Dzik *et al.*, 2000; Ravhon *et al.*, 2000; Elting *et al.*, 2001; Kwee *et al.*, 2003; Popovic-Todorovic *et al.*, 2003; Yong *et al.*, 2003). In addition, we found that stimulated inhibin B was better than stimulated estradiol, in agreement with Kwee and co-authors (2003). The secretion of inhibin B, FSH and estradiol




Figure 2. Correlation between AFC and follicular phase inhibin B and AMH.

Table III. Significant Pearson’s correlation coefficients between AFC and endocrine markers

Variable	<i>r</i>
Follicular phase variables	
Basal inhibin B (pg/ml)	0.708 ^c
Stimulated inhibin B (pg/ml)	0.788 ^c
Δ inhibin B (pg/ml)	0.731 ^b
Basal AMH (pmol/l)	0.759 ^c
Stimulated AMH (pmol/l)	0.788 ^c
Stimulated estradiol (pmol/l)	0.451 ^a
Luteal phase variables	
Basal inhibin B (pg/ml)	0.451 ^a
Stimulated inhibin B (pg/ml)	0.477 ^a
Δ inhibin B (pmol/l)	0.465 ^a
Basal AMH (pmol/l)	0.615 ^c
Stimulated AMH (pmol/l)	0.511 ^b

^a*P* < 0.05, ^b*P* < 0.01, ^c*P* < 0.001.

is mutually co-modulated. Very small antral follicles secrete inhibin B, but not estradiol, in response to FSH stimulation. The extent of inhibin B response to standard FSH dose reflects the size of the cohort of healthy recruitable follicles. These follicles are present in the ovaries during both the luteal and the follicular phases. Indeed, we demonstrated that the degree of serum inhibin B response to standard exogenous FSH stimulation was similar between the follicular and the luteal phase, in accordance with Yong and co-investigators (2003). In addition, we found that early follicular and mid-luteal serum AMH levels were very similar, in accordance with Cook and co-workers (2000). The option to perform the test in either phase is more convenient to the patient. Currently used methods must be performed

Table IV. Comparison between pregnant and non-pregnant women

Variable	Pregnant (n = 26)	Non-pregnant (n = 30)
Age (years)	29.5 ± 4.4	30.6 ± 4.9
BMI (kg/m ²)	23.6 ± 4.7	23.6 ± 5.3
No. of treatment cycles	2.5 ± 2.5	1.5 ± 0.8
Follicular phase variables		
Basal FSH (IU/l)	6.0 ± 1.5	8.4 ± 3.5
Basal inhibin B (pg/ml)	98.2 ± 96.1	138.8 ± 200.5
Stimulated inhibin B (pg/ml)	239.8 ± 249.0	219.0 ± 240.8
Δ inhibin B (pg/ml)	141.6 ± 159.9	80.2 ± 60.6
Basal AMH (pmol/l)	28.1 ± 18.3 ^a	13.8 ± 9.6
Stimulated AMH (pmol/l)	28.6 ± 20.4 ^a	12.7 ± 7.2
Basal estradiol (pmol/l)	183 ± 81	196 ± 94
Stimulated estradiol (pmol/l)	307 ± 202	348 ± 198
AFC	26.4 ± 16.5	21.4 ± 12.5
Ovarian volume (ml)	25.0 ± 29.3	13.7 ± 6.0
Luteal phase variables		
Basal inhibin B (pg/ml)	28.9 ± 38.1	43.6 ± 48.7
Stimulated inhibin B (pg/ml)	110.2 ± 118.2	89.8 ± 104.1
Δ inhibin B (pg/ml)	78.0 ± 88.8	46.2 ± 64.0
Basal AMH (pmol/l)	25.2 ± 14.3 ^b	14.2 ± 9.5
Stimulated AMH (pmol/l)	28.4 ± 15.8 ^b	13.8 ± 8.8
Basal estradiol (pmol/l)	366 ± 182	379 ± 138
Stimulated estradiol (pmol/l)	508 ± 363	718 ± 240

^aP < 0.02, ^bP < 0.005, Student's *t*-test

in the early follicular phase and some, such as the CCCT, have added inconvenience since this test takes longer than a week to be performed.

In contrast to the combination of ultrasonic and endocrine parameters, which could predict ovarian response, the only significant predictor of the probability of achieving a pregnancy was AMH. The pregnancy rate in the entire group was 46%. The best positive and negative predictive values were 67 and 61%, respectively, and the ROC_{AUC} was 0.75, which, although significant, gives only a fair ability to predict pregnancy. Even so, AMH added a considerable prognostic value: The probabilities of a pregnancy for women with serum AMH ≥18 pmol/l or <18 pmol/l are 67 and 39%, respectively. Recently, Hazout *et al.* (2004) also showed that day 3 serum AMH had a greater independent contribution in predicting pregnancy following IVF treatment than inhibin B, FSH or estradiol. On the contrary, very recently, Penarrubia *et al.* (2005) found in a heterogeneous group of women that serum AMH levels, either basal or following 4 days of FSH stimulation, were not useful in prediction of pregnancy following IVF treatment. Yet, basal and stimulated day 5 AMH levels were significantly lower in women whose cycles were cancelled because of a poor ovarian response. Therefore, definite clinical applicability of AMH measurement as a predictor of pregnancy in various populations requires further studies in a large group of patients.

Before the use of AMH, it was concluded that

inhibin B reflects ovarian reserve but is less useful at predicting pregnancy (Hall *et al.*, 1999). In a recent meta-analysis, Hendriks *et al.* (2005) found that although AFC, and to a lesser extent day 3 FSH, performed well in the prediction of poor ovarian response, both failed in predicting pregnancy. Ongoing pregnancy rates depend on ovarian reserve and on many other factors such as sperm parameters, factors influencing fertilization, implantation and abortion. Therefore, in small series,

factors found to predict oocyte number may not predict the probability of pregnancy at the same statistical significance. However, an important factor beside the oocyte quantity that determines the chance of pregnancy is oocyte quality. It was shown that in young women with low ovarian reserve, oocyte quality, but not quantity, could predict pregnancy

(van Rooij *et al.*, 2004). AFC and the associated endocrine markers for follicular number could predict oocyte number, but not inevitably oocyte quality. Female age, which correlates with oocyte quality, was shown to be superior to inhibin B levels at predicting pregnancy in IVF (Hall *et al.*, 1999; Creus *et al.*, 2000). Since all patients in our study were young

(<38 years), other factors related to oocyte quality could be identified. A direct marker of oocyte quality has yet to be found. However, it has been shown that serum insulin-like growth factor-I (IGF-I)/IGF-binding protein-1 (IGFBP-1), but not inhibin B, indicated oocyte quality in assisted reproduction treatments (Fried *et al.*, 2003).

Our results may support the assumption that there is an association between AMH and oocyte quality. This issue requires further studies in a large group of patients.

Prediction of the chance of pregnancy allows physicians to provide the patients with information about their prognosis and consider other treatment options, such as gamete donation or adoption. Prediction of ovarian response is additionally important because it may help to optimize the stimulation protocol for achieving a better response, in both low and high responders (Kligman and Rosenwaks, 2001; Popovic-Todorovic *et al.*, 2003). In the current study, we found that either ultrasonic (AFC) or endocrine assessment (basal AMH and stimulated inhibin B) could predict ovarian response, while the only predictor for pregnancy was either follicular or luteal phase AMH level.

Acknowledgments

The authors are grateful to the nursing and secretarial staff of the IVF Unit in Shaare-Zedek Medical Center for their assistance, to Taly Avraham-Bdolach for statistical analysis of the results, and to Shunit Damary for her participation in the recruitment of patients.

References

- Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD and te Velde ER (2002) Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. *Fertil Steril* 77,328–336.
- Bancsi LF, Broekmans FJ, Mol BW, Habbema JD and te Velde ER (2003) Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. *Fertil Steril* 79,1091–1100.
- Bancsi LF, Broekmans FJ, Looman CW, Habbema JD and te Velde ER (2004) Predicting poor ovarian response in IVF: use of repeat basal FSH measurement. *J Reprod Med* 4,187–194.
- Chang MY, Chiang CH, Hsieh TT, Soong YK and Hsu KH (1998) Use of the antral follicle count to predict the outcome of assisted reproductive technologies. *Fertil Steril* 69,505–510.
- Chuang CC, Chen CD, Chao KH, Chen SU, Ho HN and Yang YS (2003) Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. *Fertil Steril* 79,63–68.
- Cook CL, Siow Y, Taylor S and Fallat ME (2000) Serum mullerian-inhibiting substance levels during normal menstrual cycles. *Fertil Steril* 73,859–861.

- Creus M, Penarrubia J, Fabregues F, Vidal E, Carmona F, Casamitjana R, Vanrell JA and Balasch J (2000) Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. *Hum Reprod* 15,2341–2346.
- de Vet A, Laven JS, de Jong FH, Themmen AP and Fauser BC (2002) Anti-Müllerian hormone serum levels: a putative marker for ovarian aging. *Fertil Steril* 77,357–362.
- Dumesic DA, Damarzio MA, Session DR, Famuyide A, Lesnick TG, Thornhill AR and McNeilly AS (2001) Ovarian morphology and serum hormone markers as predictors of ovarian follicle recruitment by gonadotropins for in vitro fertilization. *J Clin Endocrinol Metab* 86,2538–2543.
- Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, Uilenbroek JT, Grootegoed JA and Themmen AP (2002) Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. *Endocrinology* 143,1076–1084.
- Dzik A, Lambert-Messerlian G, Izzo VM, Soares JB, Pinotti JA and Seifer DB (2000) Inhibin B response to EFFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. *Fertil Steril* 74,1114–1117.
- Eldar-Geva T, Margalioth EJ, Ben-Chetrit A, Gal M, Robertson DM, Healy DL, Diamant YZ and Spitz IM (2002) Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocytes to be retrieved in normal and low responders. *Hum Reprod* 17,2331–2337.
- Elting MW, Kwee J, Schats R, Rekers-Mombarg LT and Schoemaker J (2001) The rise of estradiol and inhibin B after acute stimulation with follicle-stimulating hormone predict the follicle cohort size in women with polycystic ovary syndrome, regularly menstruating women with polycystic ovaries, and regularly menstruating women with normal ovaries. *J Clin Endocrinol Metab* 86,1589–1595.
- Faddy MJ and Gosden RG (1996) A model conforming the decline in follicle numbers to the age of menopause in women. *Hum Reprod* 11,1484–1486.
- Fanchin R, deZiegler D, Olivennes F, Taieb J, Dzik A and Frydman R (1994) Exogenous follicle stimulating hormone ovarian reserve test (EFFORT): a simple and reliable screening test for detecting poor 'responders' in in-vitro fertilization. *Hum Reprod* 9,1607–1611.
- Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R and Taieb J (2003) Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. *Hum Reprod* 18,323–327.
- Frattarelli JL, Lauria-Costab DF, Miller BT, Bergh PA and Scott RT (2000) Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. *Fertil Steril* 74,512–517.
- Fried G, Remaues K, Harlin J, Krog E, Csemiczky G, Aanesen A and Tally M. Inhibin B predicts oocyte number and the ratio IGF-I/IGFBP-1 may indicate oocyte quality during ovarian hyperstimulation for in vitro fertilization. *J Assist Reprod Genet.* 2003; 20:167–76.
- Galtier-Dereure F, De-Bouard V, Picto MC, Vergnes C, Humeau C, Bringer J and Hedon B (1996) Ovarian reserve test with the gonadotrophin-releasing hormone agonist buserelin: correlation with in-vitro fertilization outcome. *Hum Reprod* 11,1393–1398.
- Garcia JE, Padilla SL, Bayati J and Baramki TA (1990) Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. *Fertil Steril* 53,302–305.
- Hall JE, Welt CK and Cramer DW (1999) Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. *Hum Reprod* 14,409–415.
- Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM and Cohen-Bacrie P (2004) Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. *Fertil Steril* 82,1323–1329.
- Hendriks DJ, Mol BW, Bancsi LF, Te Velte ER and Broekmans FJ (2005) Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. *Fertil Steril* 83,291–301.
- Kligman I and Rosenwaks Z (2001) Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. *Fertil Steril* 76,1185–1190.
- Kwee J, Elting MW, Schats R, Bezemer PD, Lambalk CB and Schoemaker J (2003) Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. *Hum Reprod* 18,1422–1427.
- Lass A, Skoll J, McVeigh E, Margara R and Winston RM (1997) Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization can predict poor response. *Hum Reprod* 12,294–297.
- Mausner SR and Oehninger S (1988) The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. *Fertil Steril* 50,298–307.
- Navot D, Rosenwaks Z and Margalioth EJ (1987) Prognostic assessment of female fecundity. *Lancet* 2,645–647.
- Pangas SA, Rademaker AW, Fishman DA and Woodruff TK (2002) Localization of the activin signal transduction components in normal human ovarian follicles: implications for autocrine and paracrine signaling in the ovary. *J Clin Endocrinol Metab* 87,2644–2657.
- Pellicer A, Ardiles G, Neuspiller F, Remohi J, Simon C and Bonilla-Musoles F (1998) Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. *Fertil Steril* 70,671–675.
- Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, Carmona F, Vanrell JA and Balasch J (2005) Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment. *Hum Reprod* 20,915–922.
- Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM and Andersen AN (2003) A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. *Hum Reprod* 18,781–787.
- Ranieri DM, Quinn F, Makhlof A, Khadum I, Ghutmi W, McGarrigle H, Davies M and Serhal P (1998) Simultaneous evaluation of basal follicle-stimulating hormone and 17 beta-estradiol response to gonadotropin-releasing hormone analogue stimulation: an improved predictor of ovarian reserve. *Fertil Steril* 70,227–233.
- Ravhon A, Lavery S, Michael S, Donaldson M, Margara R, Trew G and Winston R (2000) Dynamic assays of inhibin B and oestradiol following busserelin acetate administration as predictors of ovarian response in IVF. *Hum Reprod* 15,2297–2301.
- Scott RT Jr, Hofmann GE, Oehninger S and Muasher SJ (1990) Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. *Fertil Steril* 54,297–302.
- Seifer DB, MacLaughlin DT, Christian BP, Feng B and Shelden RM (2002) Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. *Fertil Steril* 77,468–471.
- Syrop CH, Dawson JD, Husman KJ, Sparks AE and Van Voorhis BJ (1999) Ovarian volume may predict assisted reproductive outcomes better than follicle stimulating hormone concentration on day 3. *Hum Reprod* 14,1752–1756.
- Tinkanen H, Blauer M, Laippala P, Tuohimaa P and Kujansuu E (1999) Prognostic factors in controlled ovarian hyperstimulation. *Fertil Steril* 72, 932–936.
- Tomas C, Nuojua-Huttunen S and Martikainen H (1997) Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotropins in in-vitro fertilization. *Hum Reprod* 12,220–223.
- van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH and Themmen AP (2002) Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. *Hum Reprod* 17,3065–3071.
- van Rooij IA, de Jong E, Broekmans FJ, Looman CW, Habbema JD and te Velde ER (2004) High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. *Fertil Steril* 81,1478–1485.
- Winslow KL, Toner JP, Brzyski RG, Oehninger SC, Acosta AA and Muasher SJ (1991) The gonadotropin-releasing hormone agonist stimulation test—a sensitive predictor of performance in the flare-up in vitro fertilization cycle. *Fertil Steril* 56,711–717.
- Yong PY, Baird DT, Thong KJ, McNeilly AS and Anderson RA (2003) Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation. *Hum Reprod* 18,35–44.

Submitted on April 8, 2005; resubmitted on June 6, 2005; accepted on June 14, 2005